Skip to main content

Table 1 Baseline patient and treatment characteristics: (n = 48)

From: Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer

Median Age (range) 70 years (47.1 – 85.2)
Median Pre-Treatment PSA (range) 10.0 ng/mL (3.6 – 150.0)
 ≥20 ng/mL 8 (17 %)
Gleason Score  
 7 27 (56 %)
  3 + 4 15 (31 %)
  4 + 3 12 (25 %)
 8-10 21 (44 %)
T Stage  
 T1c 12 (25 %)
 T2a 13 (27 %)
 T2b 3 (6 %)
 T3a,b 20 (42 %)
# High Riska 34 (71 %)
Median Duration HT (range) 6 months (0 – 28)
 None 3 (6 %)
 3 months 12 (25 %)
 4–6 months 15 (31 %)
 7–12 months 8 (17 %)
 24–28 months 7 (15 %)
 Unknown 3 (6 %)
CTV Dose  
 19 Gy 23 (48 %)
 21 Gy 25 (52 %)
Median Follow-up (range) 42.7 months (5.3 – 82.9)
# PSA Follow-up Measurements  
 Median (range) 8.5 (1 – 24)
 Median Post HT (range) 7 (1 – 19)
  1. aHigh Risk is defined as pretreatment ≥20 ng/mL, GS 8–10 or T stage 3